Literature DB >> 23417896

Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma.

Francesco Giovinazzo1, Giovanni Butturini, Daniela Monsellato, Giuseppe Malleo, Giovanni Marchegiani, Claudio Bassi.   

Abstract

In the current study, short- and long-term outcomes after aggressive surgical treatment for gastrinoma were evaluated. From August 1990 to August 2009, 20 patients diagnosed with Zollinger Ellison syndrome were reviewed. Eleven pancreaticoduodenectomies, three total pancreatectomies, four lymph node dissections, four enucleations and two palliative procedures were performed. Four (27.8 %) patients had disease associated with MEN1 syndrome, 13 (72.2 %) had sporadic gastrinomas (SG) and 3 had disease of unknown primary origin. No in-hospital mortality was observed. After radical resection, lymph node metastasis was present in 82 % of the cases. Eight percent of patients who underwent radical resection developed recurrence compared with 100 % of those who underwent enucleoresection (p = 0.03). Average time to recurrence in patients with sporadic gastrinoma was 66.7 months (confidence interval (CI) 62.9-70.5) in those treated with enucloeresection compared to 181.1 months (CI 124.3-237.8) in the radical resection group (p = 0.007). One recurrence was observed in the MEN1 group. Based on post-operative mortality, recurrence and lymph node metastasis, our data suggest that patients with gastrinoma should undergo abdominal exploration with aggressive resection of the primary tumour and regional lymph nodes in place of conservative treatment.

Entities:  

Mesh:

Year:  2013        PMID: 23417896     DOI: 10.1007/s13304-013-0201-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  33 in total

Review 1.  Pancreatic tumours as part of the MEN-1 syndrome.

Authors:  Göran Akerström; Ola Hessman; Per Hellman; Britt Skogseid
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-10       Impact factor: 3.043

2.  Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome.

Authors:  J A Norton; H R Alexander; D L Fraker; D J Venzon; F Gibril; R T Jensen
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

Review 3.  Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1.

Authors:  Jeffrey A Norton; Tony D Fang; Robert T Jensen
Journal:  J Natl Compr Canc Netw       Date:  2006-02       Impact factor: 11.908

4.  Surgery to cure the Zollinger-Ellison syndrome.

Authors:  J A Norton; D L Fraker; H R Alexander; D J Venzon; J L Doppman; J Serrano; S U Goebel; P L Peghini; P K Roy; F Gibril; R T Jensen
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

5.  Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form.

Authors:  F Gibril; D J Venzon; J V Ojeaburu; S Bashir; R T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

Review 6.  The role of surgery in the management of islet cell tumors.

Authors:  D L Fraker; J A Norton
Journal:  Gastroenterol Clin North Am       Date:  1989-12       Impact factor: 3.806

Review 7.  Surgical treatment of sporadic gastrinoma.

Authors:  Kerstin Lorenz; Henning Dralle
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 8.  Role of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome.

Authors:  R Delcore; S R Friesen
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

9.  Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome.

Authors:  S Bonfils; J H Landor; M Mignon; P Hervoir
Journal:  Ann Surg       Date:  1981-12       Impact factor: 12.969

Review 10.  Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas.

Authors:  V Fendrich; P Langer; J Waldmann; D K Bartsch; M Rothmund
Journal:  Br J Surg       Date:  2007-11       Impact factor: 6.939

View more
  6 in total

Review 1.  Gastrinomas: Medical or Surgical Treatment.

Authors:  Jeffrey A Norton; Deshka S Foster; Tetsuhide Ito; Robert T Jensen
Journal:  Endocrinol Metab Clin North Am       Date:  2018-09       Impact factor: 4.741

Review 2.  The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines.

Authors:  Wouter T Zandee; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2018-01-10       Impact factor: 4.914

3.  From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor.

Authors:  Allon Eyal; Alain Sueissa; Eyal Braun; Mohammad Ebrahim Naffaa
Journal:  BMJ Case Rep       Date:  2014-10-01

4.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 5.  Zollinger-Ellison syndrome: recent advances and controversies.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Curr Opin Gastroenterol       Date:  2013-11       Impact factor: 3.287

6.  Comparison study of gastrinomas between gastric and non-gastric origins.

Authors:  Song-Fong Huang; I-Ming Kuo; Chao-Wei Lee; Kuang-Tse Pan; Tse-Ching Chen; Chun-Jung Lin; Tsann-Long Hwang; Ming-Chin Yu
Journal:  World J Surg Oncol       Date:  2015-06-16       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.